Alzheimer’s Drugs Fail to Deliver ‘Clinically Meaningful’ Benefits, Landmark Review Finds

After decades of research and billions spent, the most promising class of Alzheimer’s drugs—antibodies designed to clear toxic amyloid plaques from the brain—have been dealt a major blow by an independent analysis. A rigorous review by the Cochrane Collaboration, published in April 2026, concludes that while these drugs do sluggish cognitive decline in some patients, the effect is far too modest to justify their staggering cost or serious side effects like brain swelling and bleeding.

The findings have ignited a fierce scientific debate, with some experts calling the review flawed and others warning that the drugs—licensed globally but rejected by the UK’s NHS—may offer little more than a false hope to desperate patients and families. With an 18-month course costing up to £90,000 privately, the question now is: Are these drugs worth the price—or even the risk?

Key takeaway: The Cochrane review analyzed 17 clinical trials involving 20,342 volunteers and found that amyloid-clearing drugs reduced cognitive decline by an average of 0.39 points on a 14-point scale over 18 months—a statistically significant but clinically irrelevant improvement for most patients.

Why the New Analysis Matters

Alzheimer’s disease affects 55 million people worldwide, with numbers set to triple by 2050 as populations age (Mayo Clinic). For the first time, drugs like donanemab and lecanemab—approved by the U.S. FDA and other regulators in 2023–2024—were shown to slow the disease’s progression. But the Cochrane review, published in The BMJ, reveals a critical gap: slowing is not the same as stopping or reversing the devastation of Alzheimer’s.

The drugs work by targeting beta-amyloid plaques, sticky protein deposits that accumulate between brain cells, disrupting communication and accelerating memory loss. Early trials of donanemab and lecanemab showed reductions in plaque buildup—but the Cochrane team found that these reductions translated to only a 22% slower decline in cognitive function over 18 months. For comparison, that’s roughly the difference between losing one additional month of mental function per year compared to untreated patients.

What the Cochrane Review Actually Says

The analysis pooled data from 17 randomized controlled trials, including the pivotal Phase 3 studies of donanemab (TRAILBLAZER-ALZ 2) and lecanemab (CLARITY-AD). Key findings:

• Cognitive benefit: Patients on amyloid-clearing drugs experienced an average decline of 0.39 points on the Clinical Dementia Rating-Sum of Boxes (CDR-SB) scale (range: 0–14) over 18 months, compared to 0.65 points in the placebo group. While statistically significant, this translates to a delay of about 4–6 months in reaching a milder dementia threshold.
• Side effects: 1 in 5 patients (20%) experienced serious adverse events, including brain swelling (ARIA-E) in 12% and brain bleeding (ARIA-H) in 5%. Some cases required hospitalization.
• Cost-effectiveness: At £90,000 for an 18-month course (or ~$115,000 USD), the drugs would need to demonstrate a 3-point reduction on the CDR-SB to be considered cost-effective by standard healthcare thresholds—a bar they did not meet.

The review’s lead author, Dr. Gillian Mead, a Cochrane neurology researcher, emphasized that no single drug has yet shown a meaningful impact on patients’ daily lives. “We’re not saying these drugs are useless,” she told the BBC. “But the evidence suggests they’re not the breakthrough many had hoped for.”

Scientists Clash Over the Findings

The Cochrane review has sparked a public scientific feud. Critics, including researchers who developed the drugs, argue the analysis overstates the harms while underestimating the benefits. For example:

• Dr. Reisa Sperling (Brigham and Women’s Hospital), a key figure in lecanemab’s trials, called the Cochrane conclusions “misleading” in a JAMA commentary, arguing that the review ignored patient-reported outcomes and focused too narrowly on cognitive scales.
• Dr. Eric Karran (Alzheimer’s Research UK) noted that while the effect size is compact, any delay in decline is meaningful for patients and caregivers, especially in early-stage Alzheimer’s.
• Dr. Jason Karlawish (University of Pennsylvania) countered that the drugs’ lack of impact on functional decline (e.g., ability to dress oneself, manage finances) means they fail the ultimate test.

The debate highlights a broader tension: Should drugs be approved based on biological markers (like plaque reduction) or clinical outcomes (like improved quality of life)? Regulators like the FDA have historically prioritized the former, while payers like the NHS demand the latter.

Where Do These Drugs Stand Today?

The Cochrane review’s timing is critical, as governments and insurers grapple with whether to cover these expensive treatments. Here’s the current landscape:

“A False Hope”? The Real-World Impact

For families facing Alzheimer’s, the Cochrane review raises painful questions. Take the case of Margaret Harris, a 68-year-old from Manchester whose husband, John, was diagnosed with early-stage Alzheimer’s in 2024. After reading about lecanemab’s approval, the couple spent £30,000 of their savings on a year’s supply—only to see John’s memory decline no slower than expected.

“We were told it might give him more time,” Margaret said in a BBC interview. “But time for what? He still can’t recognize our daughter. The drug didn’t change that.”

Experts warn that the psychological burden of these drugs—combined with their physical risks—may outweigh any modest benefits. “For every patient who experiences a slight delay, there’s another who suffers a stroke or brain bleed from the treatment itself,” said Dr. Clive Ballard, a dementia researcher at Stirling University.

What Happens Now?

The Cochrane review is unlikely to be the final word. Here’s what’s on the horizon:

• Ongoing trials: Phase 4 studies of donanemab and lecanemab are examining longer-term outcomes (beyond 18 months) and combination therapies (e.g., with tau-targeting drugs). Results are expected in 2027–2028.
• Regulatory reassessment: The EMA (European Medicines Agency) is reviewing new data and may update its stance on lecanemab by June 2026.
• Alternative approaches: Research into tau protein therapies (which may address Alzheimer’s core pathology more directly) and lifestyle interventions (diet, exercise, cognitive training) is accelerating.
• Patient advocacy: Groups like the Alzheimer’s Association are pushing for better early detection and improved palliative care, arguing that current treatments fail to address the root cause.

The next major checkpoint is the EMA’s Committee for Medicinal Products for Human Use (CHMP) meeting on June 15, 2026, where experts will debate whether to recommend lecanemab for EU-wide approval—or whether the Cochrane findings should lead to restrictions.